Plain-English translation of NCT07226765 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called to see if it can help treat obstructive sleep apnea—a condition where breathing repeatedly stops and starts during sleep. The medication is being compared to a placebo (a fake injection) over one year in adults with sleep apnea who are overweight or obese and not currently using a PAP (breathing) machine.
Many people with sleep apnea don't use or can't tolerate PAP therapy, which is the standard treatment. This trial explores whether this medication might offer an alternative way to improve sleep apnea by helping with both the condition itself and weight management.
You likely qualify if…
You likely don't qualify if…
You would receive either the medication or a placebo as an injection under your skin, and visit the clinic regularly over 52 weeks (about one year) for check-ups and monitoring. The study team will track how your sleep apnea changes and how well you tolerate the medication. You would not be able to start PAP therapy or other sleep apnea treatments during the trial.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States